现代妇产科进展2017，Vol.26Issue(5)：325-328,332,5.DOI:10.13283/j.cnki.xdfckjz.2017.05.002
白蛋白结合型紫杉醇联合铂类或异环磷酰胺治疗复发性卵巢癌的疗效及安全性分析
Efficacy and safety of albumin-bound paclitaxel combined with platinum or ifosfamide in the treatment of recurrent ovarian cancer
摘要
Abstract
Objective:To observe the clinical efficacy and safety of albumin-bound paclitaxel combined with platinum or ifosfamide in the treatment of recurrent ovarian cancer.Methods:46 cases of recurrent ovarian cancer patients received different formulations of paclitaxel combined with platinum or ifosfamide were analyzed retrospectively.26 platinum-sensitive patients with recurrent ovarian cancer were treated with either albumin-bound paclitaxel or solvent-based paclitaxel combined with carboplatin.20 platinum-resistant patients with recurrent ovarian cancer were treated with albumin-bound paclitaxel or solvent-based paclitaxel combined with ifosfamide,every 21 days a cycle,until complete remission and consolidation for another two courses or disease progression or intolerable adverse reactions.The clinical effects,side effects and prognosis of four groups were compared.Results:In platinum-sensitive patients,the complete remission rate was 60% in albumin-bound paclitaxel-treated patients and 18.8% in solvent-based paclitaxel-treated patients (P<0.05).The objective response rates were 90% and 75%,respectively.In platinum-resistant patients,the complete remission rate was 16.7% in albumin-bound paclitaxel group and 0% in solvent-based paclitaxel group (P<0.05).The objective response rates were 66.7% and 57.1% respectively.In platinum-sensitive relapsed patients,the median progression-free survival (PFS) of albumin-bound paclitaxel and solvent-paclitaxel groups were 10.25 and 7.5 months respectively (P<0.05).In platinum-resistant relapsed patients,the PFS of albumin-bound paclitaxel and solvent-based paclitaxel groups were 7.8 and 5.6 months respectively (P<0.05).The main adverse effects of the four groups are bone marrow suppression and gastrointestinal reaction.In platinum-sensitive or platinum-resistant patients,there were no significant differences in the incidence of Ⅲ~Ⅳ grade adverse reactions between albumin-bound paclitaxel and solvent-based paclitaxel groups (P>0.05).Conclusion:Compared with solvent-based paclitaxel,albumin-bound paclitaxel based chemotherapy regime has a higher complete remission rate,prolonger PFS and no more toxicity in platinum-sensitive or platinum-resistant recurrent ovarian cancer patients.关键词
白蛋白结合型紫杉醇/卵巢癌/无进展生存时间/不良反应Key words
Albumin-bound paclitaxel/Ovarian cancer/Progression-free survival/Adverse分类
医药卫生引用本文复制引用
熊云棋,狄文,吴霞..白蛋白结合型紫杉醇联合铂类或异环磷酰胺治疗复发性卵巢癌的疗效及安全性分析[J].现代妇产科进展,2017,26(5):325-328,332,5.基金项目
国家自然基金面上项目(No:81472843) （No:81472843）
上海市科学技术委员会上海市科研计划项目(No:14ZR1424700) （No:14ZR1424700）
